



[January 27, 2009 01:59 PM Eastern Time](#)

Neugenesis Announces the Retirement of Ronald E. Cape as Chairman of its Board of Directors

BURLINGAME, Calif.--([BUSINESS WIRE](#))--Neugenesis Corporation, a company with proven and proprietary technology for rapid and inexpensive production and improvement of multivalent vaccines for infectious diseases and other high value biopharmaceutical drugs including monoclonal antibodies today announced that Ronald E. Cape has resigned his appointment as the company's Chairman of the Board. Dr. Cape has been Chairman of Neugenesis since 1995, and has been instrumental in helping the Company chart its path forward from a small start up to a thriving development stage organization with bio-defense contracts from the Federal Government. Dr. Cape was the co-founder, Chairman and CEO of Cetus Corporation, a world leader and pioneer in genetic engineering, including the discovery and development of the polymerase chain reaction (PCR), for which Cetus scientist Kary Mullis received the Nobel Prize. Cetus later merged with Chiron Corporation. Dr. Cape was the founding chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc. He was also a founding member of the Biotechnology Industry Organization and served as its President for three years.

Dr. Cape is a fellow of the American Academy of Arts and Sciences, the American Academy of Microbiology and the American Association for the Advancement of Science. He is the recipient of many awards, including the 2007 Biotechnology Heritage Award, and has held dozens of prestigious board positions in the public and private sectors. In recent years, Dr. Cape has been an investor in the field of biotechnology and a board member of various public and private companies. He has also served on the boards of Princeton University, Rockefeller University, the Whitehead Institute at MIT, and the Board of Regents of the NIH National Library of Medicine.

In announcing his retirement, Dr. Cape said, "There is finally recognition that Neugenesis' proprietary technology could respond much more quickly than the current egg-based technology to new knowledge about seasonal influenza strains, even after the flu' season has begun. As a non-egg way to create a vaccine to fight the seasonal flu', this proprietary fungal-based technology also represents a way to rapidly produce a vaccine for the deadly bird flu'. I am gratified that the U.S. Department of Defense has recognized the potential of Neugenesis' intellectual property, and has provided the funds necessary to demonstrate that promise."

"I have known Ron Cape since the early 1980's when I accepted an offer to become a consultant for Cetus," said W. Dorsey Stuart, CEO and Co-Founder, Neugenesis. "Ron has constantly been a source of ideas and directions for our company and for the biotechnology industry at large." "I regret the loss of such an experienced and distinguished Board member but I respect and support his desire to spend more time with his extended family."

As a token of respect for his service to the Company, Neugenesis has named Dr. Cape, Director Emeritus. As such, he has agreed to advise the Company from time to time as it continues to move forward. The Board has elected Dr. Stuart to replace Dr. Cape as Chairman.

Neugenesis Corporation is a privately held biotechnology company which has been able to generate a diverse set of technology platforms and products for the world wide biotechnology and biopharmaceutical industry. In addition to its emerging position in vaccines, the Company holds strong intellectual property positions in the areas of production of recombinant monoclonal antibodies, cell based gene directed evolution and cell based combinatorial biology.

For further information, please visit the Neugenesis web site at <http://www.neugenesis.com> or contact Dr. W. Dorsey Stuart at info@neugenesis.com